anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
See Table 1 for dosage recommendations for acute and maintenance treatment of bipolar I disorder in adult and pediatric patients (7 to 17 years). 

Obtain serum lithium concentration assay after 3 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized. Fine hand tremor, polyuria, and thirst may occur during initial therapy for the acute manic phase and may persist throughout treatment. Nausea and general discomfort may also appear during the first few days of lithium administration. These adverse reactions may subside with continued treatment, concomitant administration with food, or temporary reduction or cessation of dosage.

Table 1. Lithium Dosing for Bipolar I Disorder
The present invention relates to seven-transmembrane proteins, including proteins that function as receptors belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the seven-transmembrane proteins/receptors. The invention further relates to methods using the seven-transmembrane protein/receptor polypeptides and polynucleotides as a target for diagnosis and treatment in seven-transmembrane protein/receptor-mediated and related disorders. The invention further relates to drug-screening methods using the seven-transmembrane protein/receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the seven-transmembrane protein/receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
Physical activity is essential for all age groups, across all comorbidities and geriatric syndromes; it has been described as the 'ideal' intervention for aging. Increasing physical activity among homebound, multimorbid, African American (AA) older adults (OAs) requires a shift in interventions to target the older adult-care partner (CP) pair (dyad) and to test innovative vehicles for remote intervention delivery. Our research goal is to create an evidence-based intervention that leverages technology to reach multimorbid OA-CP dyads in the home, promotes long-term mobility and social engagement among those least able to access community resources, and empowers informal care partners with tools. We developed a socially-motivated exercise tool for multimorbid OA-CP dyads called EngAGE that leverages voice-activated technology. We propose to conduct a 6-month, randomized, in-home trial of EngAGE (intervention) versus paper exercise handouts (usual care) in 124 multimorbid, homebound, AA OA-CP dyads recruited from 2 hospital systems and the community. Our overall hypothesis is that EngAGE will improve both physical and social function of older adults.

All OA subjects will undergo an in-home baseline visit where we will collect data about physical function, social function, activity and frailty. OA-CP dyads will be randomized (1:1) to a physical activity intervention: either EngAGE or usual care. All subjects will be asked to complete exercises 3-6 times per week. Care Partners will be instructed to encourage their Older Adult partner to perform physical activities on a regular basis. There is a two week Run-In Period to troubleshoot the EngAGE app and acclimate the OA subjects to the study intervention. OA subjects will be monitored via phone visits on a monthly basis. In home study visits will take place at month 3 and month 6. Data about OA subject physical function, social function, activity and frailty will be collected at these visits.
Preparation of 9-deoxo-9(Z) hydroxyimino erythromycin A (I) in the form of a solvate with a dialkyl ketone, from 9-deoxo-9(E) hydroxyimino erythromycin A (II).   9-Deoxo-9(Z) hydroxyimino erythromycin A is of formula (I) and is prepared by treating (II) in water with a base, adjusting to pH 9 - 11, adding an organic solvent and optionally concentrating the solution formed to give (I). The aqueous solution of (II) used as starting material may further contain a dialkyl ketone that forms a crystallizable solvate with (I), such as acetone. The base used is preferably an alkali or alkaline earth metal, or ammonium hydroxide, a carbonate or an alkoxide, 1-10, and preferably 2 moles being used per mole of (II). The isomerization is effected at 10 - 25 deg C, preferably at 20 deg C. After the initial stage is complete an acid, such as acetic, or hydrochloric acid or sodium bicarbonate is added, preferably to pH 9.5 - 10, and the temperature is maintained below 20 deg C, especially around 10 deg C. The organic solvent that is added is preferably an ester, especially ethyl acetate. Concentration of the resultant solution takes place at a temperature below 35 deg C.  An Independent claim is included for (I) in the form of a diketone solvate, especially with acetone.
BACKGROUND: Highlighted by the rise of COVID-19, climate change, and conflict, socially vulnerable populations are least resilient to disaster. In infectious disease management, mathematical models are a commonly used tool. Researchers should include social vulnerability in models to strengthen their utility in reflecting real-world dynamics. We conducted a scoping review to evaluate how researchers have incorporated social vulnerability into infectious disease mathematical models.
METHODS: The methodology followed the Joanna Briggs Institute and updated Arksey and O'Malley frameworks, verified by the PRISMA-ScR checklist. PubMed, Clarivate Web of Science, Scopus, EBSCO Africa Wide Information, and Cochrane Library were systematically searched for peer-reviewed published articles. Screening and extracting data were done by two independent researchers.
RESULTS: Of 4075 results, 89 articles were identified. Two-thirds of articles used a compartmental model (n = 58, 65.2%), with a quarter using agent-based models (n = 24, 27.0%). Overall, routine indicators, namely age and sex, were among the most frequently used measures (n = 42, 12.3%; n = 22, 6.4%, respectively). Only one measure related to culture and social behaviour (0.3%). For compartmental models, researchers commonly constructed distinct models for each level of a social vulnerability measure and included new parameters or influenced standard parameters in model equations (n = 30, 51.7%). For all agent-based models, characteristics were assigned to hosts (n = 24, 100.0%), with most models including age, contact behaviour, and/or sex (n = 18, 75.0%; n = 14, 53.3%; n = 10, 41.7%, respectively).
CONCLUSIONS: Given the importance of equitable and effective infectious disease management, there is potential to further the field. Our findings demonstrate that social vulnerability is not considered holistically. There is a focus on incorporating routine demographic indicators but important cultural and social behaviours that impact health outcomes are excluded. It is crucial to develop models that foreground social vulnerability to not only design more equitable interventions, but also to develop more effective infectious disease control and elimination strategies. Furthermore, this study revealed the lack of transparency around data sources, inconsistent reporting, lack of collaboration with local experts, and limited studies focused on modelling cultural indicators. These challenges are priorities for future research.
PURPOSE:To readily obtain a substance adsorbing cholesterol having acidic polysaccharides of mannose, glucose, arabinose and uronic acid linked through plural forms of glycoside bonds by using a microorganism belonging to the genus Rhodococcus. CONSTITUTION:A microorganism belonging to the genus Rhodococcus, especially Rhodococcus.bronchialis (ATCC 25592) is cultured and cholesterol is then added to the resultant culture solution. The mixture solution is shaken and the supernatant thereof is acidified to collect formed precipitates. Thereby, a substance adsorbing cholesterol is obtained. The resultant substance contains mannose, glucose, galactose and arabinose at about 36:16:7:1 composition ratio and uronic acid in an amount of 10-20% based on the constituent saccharides. The above- mentioned constituent saccharides are linked through plural forms of glycoside bonds.
The intervention will be the stimulation with transcranial Direct Current Stimulation (tDCS). Each patient will undergo a 20 minutes session with anode placed on the right Dorso-Lateral Prefrontal Cortex (RDLPFC) and the cathode on the left DLPFC (LDLPFC); the tDCS will administrate a 1 mA stimulation. During the intensive treatment phase participant will undergo one stimulation/day for 5 consecutive days. After this, participants will receive one stimulation per week for 3 months with the same parameters. Device: tDCS device (E.M.S. Electromedical Systems, Bologna, Italy) with a maximum output of 5 mA and administered by two 25-cm2 sponge electrodes of rectangular shape.
Table 1 summarizes the recommended dosages of ORABLOC administered by intraoral submucosal infiltration or nerve block for various types of anesthetic dental procedures in healthy adults and pediatric patients.

The recommended dosages of ORABLOC in healthy adults serve only as a guide to the amount of anesthetic required for most routine dental procedures. The dosage to be used in adults depend on several factors such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, administer the lowest dosage that will produce the desired result.

The dosages of ORABLOC to be used in pediatric patients aged 4 to 16 years old are determined by the age and weight of the patient and the type of dental procedure.

For most routine dental procedures, ORABLOC containing epinephrine 1:200,000 is preferred. However, when more pronounced hemostasis or improved visualization of the surgical field are required, ORABLOC containing epinephrine 1:100,000 may be used.

The onset of anesthesia and the duration of anesthesia are proportional to the dosage of the local anesthetic used. Exercise caution when employing large volumes because the incidence of adverse reactions may be dose-related.
BACKGROUND: In view of the conflicting results from previous studies, the benefit of paclitaxel-coated balloons for arteriovenous fistulas is uncertain and equipoise remains. Although an industry-led trial testing the efficacy of sirolimus-coated balloons in AVFs is in progress, the benefit of sirolimus-coated balloons for arteriovenous fistulas is currently unknown. The purpose of this trial is to compare the efficacy of additional paclitaxel-coated or sirolimus-coated balloons on outcomes after a plain balloon fistuloplasty to preserve the patency of arteriovenous fistulae used for haemodialysis.
METHODS: The study design is a multicentre randomised controlled trial. Following a successful plain balloon fistuloplasty, participants will be randomised to further treatment with a paclitaxel-coated balloon, a sirolimus-coated balloon, or an uncoated control balloon. We will recruit 642 patients, each with one or two treatment segments, over a 3-year period. Patients will remain in the trial and be followed up for 1 year. The primary endpoint is time to loss of treatment segment primary patency. Cox-proportional hazards models will be used to estimate hazard ratios for the time to loss of treatment segment primary patency for each treatment group relative to the control group. Analysis of the primary endpoint will be based on treatment segments rather than participants and a shared frailty will be estimated to account for the clustering of treatment segments within patients. Secondary endpoints are time to loss of primary patency at any treatment segment; time to end of access circuit primary patency; time to AVF abandonment; number of radiological or surgical interventions; adverse events; intima-media thickness and degree of stenosis at 3 months on ultrasound; and patient quality of life assessed by EQ-5D-5L and VASQoL.
DISCUSSION: The three-armed design in this proposal will provide an answer on the efficacy of both paclitaxel- and sirolimus-coated balloons in the same trial. This trial is likely to provide a clear answer regarding the efficacy of drug-coated balloons for arteriovenous fistulas.
TRIAL REGISTRATION: ISRCTN ISRCTN40182296. Registered on 4 August 2023.
PROBLEM TO BE SOLVED: To obtain the subject preparation by including an extract from the mycelia of Agaricus blazei Murill and the mycelia culture filtrate and physiologically active substance(s) of animal origin to potentiate both moisturizing effect and epidermal fibroblast activating effect and have excellent effect for the prevention/improvement of skin aging symptoms. SOLUTION: This preparation for external use for skin contacts (A) an extract from the mycelia of Agaricus blazei Murill (FERM 4731) (pref. at 0.0001-5 wt.%) and/or mycelia culture filtrate and (B) at least one kind of physiologically active substance of animal origin (e.g. a placenta or spleen extract from mammal such as human or cattle, soluble eggshell membrane protein, basic or acidic fibroblast growth factor, epithelial cell growth factor, nucleic acid, pref. at 0.0001-5 wt.%), and pref. further, a combination of (C) 0.0001-3 wt.% of an anti-inflammatory agent, (D) 0001-10 wt.% of mucopolysaccharides (e.g. hyaluronic acid) and (E) 0.0001-5 wt.% of a 2-hydroxycarboxylic acid.
Moulded products are made from mixtures of (a) copolymers of vinyl chloride and vinyl acetate containing at least 75 per cent of vinyl chloride, and (b) acrylic and/or methacrylic acid esters, such as the methyl esters, and/or amides, alone or together with other polymerizable compounds such as styrene, by shaping the mixture, e.g. into films, granules, cords or ribbons, at a moderately increased temperature such as 40 DEG  C. in the absence of accelerating agents, and then polymerizing by the addition of accelerating agents such as benzoyl peroxide and redox and metal redox systems, such as a mixture of a peroxide with a tertiary amine, a sulphinic acid, or ferric stearate.  Also present in the polymerizable mixture may be a polymerization inhibitor such as hydroquinone, dyestuffs and/or plasticizers. Polymerization may be carried out by sprinkling accelerator on to the polymerizable mass, or by painting a solution of accelerator on to the walls of a mould in which polymerization is to be effected, followed by the application of heat or high frequency action.  The process may be applied to the manufacture of artificial teeth.  Specification 540,383 is referred to.
The hospitalization of a relative in an intensive care unit is an important stress factor for his/ her relatives and previous studies demonstrated that 33% post traumatic disorder (PTSD) following the ICU stay of their loved ones. To response to this issue specific approach have been designed to decrease the stress of the relatives named family centered care. Those approaches are based on the interaction between the ICU team and the relatives and included large time for visiting the patient in the ward. In France the restrictive measures (confinement) took to combat the SARS-CoV-2 pandemic from the 17 march 2020 impacted negatively those family centered care approach by prohibiting the visit in ICU and limiting to interaction between ICU team and relatives to phone calls. The investigators thought that this context could have for consequence an increase in relative anxiety and PTSD. The investigators designed a care intervention named OLAF in order to limit the impact of the confinement on relative psychological state. OLAF intervention permits to the two closest relatives of the patient to be contacted by a psychiatrist and could benefit from a specialized follow up. This intervention is completed by the implementation of virtual visits by video conference that were proposed to the relatives as well as video interview with the ICU team. In this study the investigators aimed to investigated the impact of this intervention to prevent the PTSD in the relatives by comparing the PTSD prevalence in a group of relatives that loved ones were hospitalized after the confinement measure but before the OLAF intervention and a group of relatives that loved ones were hospitalized during the OLAF intervention.

The relative will benefit from psychiatric interview 3 months after their loved ones leave the ICU or died to collect information by phone about the confinement situation they experiment, the satisfaction they had about the patient stay in ICU and their anxiety and depression state. Three-month, six month and twelve months after the discharge of the dead the relative information will be collected by phone about PTSD symptoms, anxiety and depression and complicated grief in case of death of the patient.
Herpes zoster (HZ) is a prevalent disease characterized by a painful rash. A multi‑country study was conducted to elicit public and physician knowledge, attitude, and practice (KAP) toward HZ disease and vaccination for the assessment of local factors influencing HZ vaccine perceptions in four Asian-Pacific countries/territories One-to-one qualitative interviews were conducted in 2022, among the public (people aged ≥ 50 years, adults with parents aged ≥ 50 years, zoster vaccine live-vaccinated individuals aged ≥ 50 years in Republic of Korea, and HZ patients; n = 78) and physicians (general practitioners and specialists; n = 24). Themes surrounding KAP toward HZ and HZ vaccination were summarized using a thematic analysis. A substantial knowledge gap related to HZ was observed among the public, including its causes, long-term impacts, and the at-risk population. There was a low perceived risk of HZ and low general awareness of HZ vaccine availability, although country/territory-specific differences existed. Fear of HZ-associated pain contributed toward vaccination intent among HZ patients and adults with parents aged ≥ 50 years. HZ-naïve adults who were encouraged to receive the vaccine by others were not motivated to do so due to optimism bias. Physicians were perceived to be a reliable source of information. However, physicians did not always proactively discuss HZ vaccination due to time constraints and a perceived need to prioritize other vaccinations including influenza and pneumococcal vaccines. Initiatives are needed to improve public awareness of HZ and its complications, in terms of overall impact on individuals and society, and highlight the important role of physicians in recommending vaccination.
The invention relates to the production of Pichia pastoris yeast and a system for purifying the recombinant allergen of Olea europaea Ole e 1 for utilization in the diagnosis and treatment of allergies. The recombinant DNA coding for allergens Ole e 1 of olive tree pollen (Olea europaea), Syr v 1 from lilac pollen (Syringa vulgaris) and Lig v 1 of privet (Ligustrum vulgare) has been cloned and expressed. Said allergens have great structural similarity amongst them and with other pollen allergens of other Oleaceae. Recombinant proteins produced in the Pichia pastoris yeast are isolated with high yields, are correctly folded and exhibit immunological properties equivalent to those of natural allergens. Hence, they can be used in diagnosis protocol and immunotherapy.The invention relates to the production in Pichia pastoris yeast and a system for purifying the recombinant allergen of Olea europaea Ole e 1 for utilization in the diagnosis and treatment of allergies. The recombinant DNA coding for allergens Ole e 1 of olive tree pollen ( Olea europaea ), Syr v 1 from lilac pollen ( Syringa vulgaris ) and Lig v 1 of privet ( Ligustrum vulgare ) has been cloned and expressed. Such allergens have great structural similarity amongst them and with other pollen allergens of other Oleaceae. Recombinant proteins produced in the Pichia pastoris yeast are isolated with high yields, are correctly folded and exhibit immunological properties equivalent to those of natural allergens. Hence, they can be used in diagnosis protocol and immunotherapy.
Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
A healthcare network is provided. A system operable to provide healthcare data to user devices in a healthcare network, the healthcare network comprising a plurality of data sources, the plurality of data sources comprising healthcare data. The system maintains a first plurality of associations between a first plurality of data sources of the plurality of data sources and healthcare data stored therein. In response to a request for healthcare data from a user device, the system determines whether the requested healthcare data can be retrieved based on the first plurality of associations. If the requested healthcare data cannot be retrieved, the system causes a second association related to a second data source that includes the requested healthcare data to be detected and stored. The system retrieves the requested healthcare data from the second data source and transmits it for receipt by the user device.
Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization.
The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis-4 index (FIB-4), and NAFLD fibrosis score (NFS) were assessed in 871 MAFLD patients who received elastography in a viral hepatitis-endemic area. The area under the receiver operating characteristic (AUROC) curve increased substantially with increasing fibrotic stage across the three biomarkers. APRI (AUROC range 0.73-0.80) and FIB-4 (AUROC range 0.66-0.82) performed better than NFS (AUROC range 0.63-0.75). When patients were divided into viral and non-viral MAFLD groups, a better AUROC of APRI (range 0.76-0.80) and FIB-4 (range 0.68-0.78) than NFS (range 0.62-70) existed only in viral MALFD but not in non-viral MAFLD. Regarding the NFS, the AUROC was higher in non-viral MAFLD (range 0.69-0.86) and outperformed viral MAFLD at all fibrotic stages. The accuracy in predicting liver fibrosis increased with the advancement of liver disease for the three biomarkers. NFS exerted better diagnostic accuracy in non-viral than in viral MAFLD patients across different fibrotic stages. The best accuracy was 91.1% using the cutoff value of -9.98 for the NFS in predicting liver cirrhosis in non-viral MAFLD patients. The APRI and FIB-4 performed better than the NFS in predicting liver fibrosis in MAFLD as a whole. The suboptimal performance and accuracy of the NFS existed only in viral MAFLD patients. Caution should be taken when assessing the NFS in MAFLD patients with viral hepatitis.
Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.
Patients and survivors complete a survey online over 20-30 minutes at baseline about COVID-19 specific psychological distress, health care utilization, health behavior, social and financial disruptions, HRQoL, their social support, perceived benefits under times of stress, and the ability to manage stress. Patients and survivors may be contacted again at 6 months and 1 year for COVID-19 research.